CITY THERAPEUTICS, INC. (CTY)
Biotechnology · market cap $1.1B
Research and calibrated estimates, not financial advice — verify before acting.
No upcoming catalysts in our calendar.
| Asset | Phase | Indication |
|---|---|---|
| PLA (Panto+Levoflox+Azithro) | Phase 3 | Helicobacter Pylori Gastritis |
| TB/Flu-05E | Phase 2 | Tuberculosis |
| High-Dose Melphalan HCL for Injection (Propylene Glycol-Free) | Phase 2 | Multiple Myeloma |
| Therapeutic Anticoagulation | Phase 3 | COVID-19 |
| Vivarin | Phase 2 | Narcolepsy |
| Diacetylmorphine | Phase 3 | Opioid Dependence |
| RSV/Flu-01E | Phase 2 | Respiratory Synctial Virus Infections |
| Cal-Mag Butyrate | Phase 2 | Gulf War Illness |
| Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole) | Phase 2 | Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer |
Daily closes through 2026-11-17. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for CTY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
